Arthneeti
AL

Alkem Laboratories Ltd

Q4 FY26Pharmaceuticals & Biotechnology

ALKEM Q4 FY26 Results & Concall Highlights: Key Takeaways

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹5,367
Market cap₹65.6K Cr
P/E27.3
Updated3 Jul 2026
Read4 min read

What the Q4 FY26 call signalled

1 of 3 strong

RevenueRank 3
MarginRank 3
CapexYes

Not discussed on this call: fundraise, order book.

The short version

- Alkem aims to grow 100 to 150 basis points higher than the overall market growth in India branded generics. - Domestic business expected to grow 100-150 basis points higher than the India market, targeting double-digit growth driven by new launches like semaglutide. - U.S.

From Alkem Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 3 Jul 2026.

Revenue & Sales Performance

Rank 3
  • Alkem aims to grow 100 to 150 basis points higher than the overall market growth in India branded generics.
  • Growth is expected to improve further with the launch and scale-up of GLP-1 (semaglutide) in India, contributing significantly to chronic segment growth.
  • Chronic segment currently forms about 22% to 23% of the business, with consistent internal improvement by at least 1% annually.
  • The trade generic business showed ~4.3% growth in FY '26, with a focus on profitability; growth is expected to improve in the coming year.
  • In the U.S., new product launches such as Tolvaptan (expected Sep-Oct 2026) will support growth, though value erosion on base products may impact.
  • Overall, the company expects to sustain or improve current growth momentum across segments, with execution and portfolio expansion key drivers.
  • International sales grew by 22.5% in FY '26; continued focus on international markets is expected to sustain healthy momentum.

Profitability & Margins

See what Alkem Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes
- Occlutech acquisition is the biggest recent investment by Alkem in the last 10 years. - No further acquisitions are planned for at least the next 12 months to focus on integrating Occlutech into Alkem MedTech. - Integration of Occlutech into Alkem MedTech business will take about 12 months. - Continued disciplined investments in expanding differentiated pipeline and operational excellence as part of long-term value creation. - Capital allocation prioritizes balancing dividend payouts with funding for R&D in biosimilars and specialty drugs. - Ongoing investments in new product launches, including semaglutide, and strengthening domestic chronic therapy business. These points reflect Alkem’s strategic investment approach focused on integrating recent acquisitions and investing in organic growth and R&D, with no immediate large-scale new capital expenditure beyond these initiatives.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pharmaceuticals Ltd
Rev 1Mar 2
2OneSource Speci.
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Alkem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • During the call, there is no explicit mention of a specific current or expected order book or pending orders for Alkem Laboratories.
  • Regarding the U.S. engine manufacturing facility, it was stated that it is early days to declare any significant new order inflows post tariffs and insourcing focus.
  • The management indicated that large companies take time to ramp up their own capacities, which affects immediate order inflow visibility.
  • No specific quantitative data or forecast on order books or pending orders was shared in the provided transcript.

Alkem Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹3.6K Cr, net profit ₹251 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Alkem Lab's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Torrent Pharmaceuticals Ltd (Q4 FY26)

    Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…

  • Kwality Pharma (Q4 FY26)

    FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…

  • RPG Life Sciences Ltd (Q4 FY26)

    Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…

  • Sai Parenteral's (Q4 FY26)

    Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Alkem Laboratories Ltd Q1 FY27 results?

- Alkem aims to grow 100 to 150 basis points higher than the overall market growth in India branded generics. - Domestic business expected to grow 100-150 basis points higher than the India market, targeting double-digit growth driven by new launches like semaglutide. - U.S.

What is Alkem Laboratories Ltd share price analysis?

Alkem Laboratories Ltd currently shows a below-average growth signal. The stock trades at a P/E of 27.3 with a market cap of ₹65,593. Investors should review the full earnings analysis for detailed insights.

Is Alkem Laboratories Ltd planning capital expenditure?

- Occlutech acquisition is the biggest recent investment by Alkem in the last 10 years.

Keep Alkem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.